<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04185584</url>
  </required_header>
  <id_info>
    <org_study_id>ADT2002-LTFU</org_study_id>
    <nct_id>NCT04185584</nct_id>
  </id_info>
  <brief_title>Long-Term Safety Follow-Up Study of SCM-AGH in Subjects Who Participated and Administered SCM-AGH in to Severe Atopic Dermatitis Clinical Trials</brief_title>
  <official_title>A Long-Term Safety Follow-Up Study of SCM AGH in Subjects Who Participated in the ADT2002 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SCM Lifescience Co., LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SCM Lifescience Co., LTD.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a long-term safety follow-up study of the Phase I/II multicenter study of SCM-AGH in
      subjects with moderate to severe atopic dermatitis. subjects will be followed up for a
      maximum period of 240 weeks after the first dose of investigational product. Only subjects
      previously enrolled in protocol ADT2002 (ClinicalTrials.gov ID: NCT04179760) will be eligible
      for this long-term follow-up protocol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects who meet all eligibility criteria for Long Term Follow Up(LTFU) study participation
      at the ADT2002 End of Treatment(EOT) visit may continue LTFU for a maximum period of up to
      240 weeks post first dose of investigational product. No additional dosing will be
      administered on this LTFU protocol.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 30, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Long-term safety assessment of SCM-AGH in subjects with moderate to severe Atopic Dermatitis(AD)</measure>
    <time_frame>Up to 5 Years</time_frame>
    <description>Number of occurrence of treatment-related adverse events (â‰¥ Grade 3 in severity (NCI-CTCAE, v5.0))</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Long-term concomitant medication assessment of SCM-AGH in subjects with moderate to severe Atopic Dermatitis(AD)</measure>
    <time_frame>Up to 5 Years</time_frame>
    <description>Number of occurrence of use of medications related to adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Outcome of unresolved Adverse Events(AEs) from ADT2002 study</measure>
    <time_frame>Up to 5 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically important physical examination findings</measure>
    <time_frame>Up to 5 Years</time_frame>
    <description>Number of abnormality in general appearance, skin, eyes/ears/nose/throat, head and neck, cardiovascular, respiratory, abdomen, extremities, lymph nodes, musculoskeletal and neurologic.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of occurrence of Abnormal, clinically significant in hematology laboratory results</measure>
    <time_frame>Up to 5 Years</time_frame>
    <description>Hematology panel: alkaline phosphatase [ALP], blood urea nitrogen, creatinine, serum aspartate aminotransferase (AST), serum alanine aminotransferase (ALT), albumin, total protein, total bilirubin, uric acid, glucose, cholesterol, sodium, potassium, chloride, calcium, phosphorus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of occurrence of Abnormal, clinically significant in chemistry laboratory results</measure>
    <time_frame>Up to 5 Years</time_frame>
    <description>Chemistry panel: hemoglobin, hematocrit, red blood cells, white blood cells (WBC), WBC differential count, platelets</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of occurrence of Abnormal, clinically significant in urinalysis laboratory results</measure>
    <time_frame>Up to 5 Years</time_frame>
    <description>Urinalysis panel: specific gravity (SG), color, pH, protein, glucose, bilirubin, blood, WBC</description>
  </secondary_outcome>
  <enrollment type="Anticipated">92</enrollment>
  <condition>Dermatitis, Atopic</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Not Applicable (Observational Study)</intervention_name>
    <description>Not Applicable (Observational Study)</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects who have received at least 1 dose of SCM-AGH in the ADT2002 study
        (ClinicalTrials.gov ID: NCT04179760)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects who provide written informed consent

          2. Subjects who have received at least 1 dose of SCM-AGH in the ADT2002 study

          3. Subjects who are willing to comply with the visit schedule and study requirements for
             reporting relevant information to the site.

        Exclusion Criteria:

        1. Subjects who are unable to comply with the visit schedule prior to Week 240 after first
        dose of SCM AGH
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gwang Seong Choi, MD-Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inha University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Howard Her</last_name>
    <phone>+82-2-6001-3543</phone>
    <email>hher@scmlifescience.com</email>
  </overall_contact>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 28, 2019</study_first_submitted>
  <study_first_submitted_qc>December 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2019</study_first_posted>
  <last_update_submitted>March 16, 2020</last_update_submitted>
  <last_update_submitted_qc>March 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SCM-AGH</keyword>
  <keyword>Atopic Dermatitis</keyword>
  <keyword>Stem cell therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

